734523-73-0

Basic information

• Product Name: (S)-2-Amino-4-{[4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-prop-1-ynyl-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)-phenyl]-methyl-carbamoyl}-butyric acid methyl ester
• CAS NO: 734523-73-0
• Molecular Weight: 558.718
• Mol File: 734523-73-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (S)-2-Amino-4-{[4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-prop-1-ynyl-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)-phenyl]-methyl-carbamoyl}-butyric acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-Amino-4-{[4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-prop-1-ynyl-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)-phenyl]-methyl-carbamoyl}-butyric acid methyl ester(734523-73-0)
• EPA Substance Registry System: (S)-2-Amino-4-{[4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-prop-1-ynyl-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)-phenyl]-methyl-carbamoyl}-butyric acid methyl ester(734523-73-0)

Safety Data

• Hazardous Substances Data: 734523-73-0(Hazardous Substances Data)

Upstream product

• 639520-83-5 N-(4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)-N-methylformamide 
• 104004-96-8 (8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-11-(4-(methylamino)phenyl)-17-(prop-1-yn-1-yl)-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one 
• 84371-65-3 mifepristone 
• 72086-72-7 N-tert-butoxycarbonylglutamic acid methyl ester 
• 298186-92-2 11β-{4-((4(S)-t-Butoxycarbonylamino-4(S)-methoxycarbonyl)butyryl-methyl-amino)phenyl}-17β-hydroxy-17α-(1-propynyl)estra-4,9-dien-3-one 

Relevant articles and documents

Liver-selective glucocorticoid antagonists: A novel treatment for type 2 diabetes

Hepatic blockade of glucocorticoid receptors (GR) suppresses glucose production and thus decreases circulating glucose levels, but systemic glucocorticoid antagonism can produce adrenal insufficiency and other undesirable side effects. These hepatic and systemic responses might be dissected, leading to liver-selective pharmacology, when a GR antagonist is linked to a bile acid in an appropriate manner. Bile acid conjugation can be accomplished with a minimal loss of binding affinity for GR. The resultant conjugates remain potent in cell-based functional assays. A novel in vivo assay has been developed to simultaneously evaluate both hepatic and systemic GR blockade; this assay has been used to optimize the nature and site of the linker functionality, as well as the choice of the GR antagonist and the bile acid. This optimization led to the identification of A-348441, which reduces glucose levels and improves lipid profiles in an animal model of diabetes.